| Characteristic . | No. . | All Patients (N = 69) . | No. . | Grade 0 (n = 42) . | No. . | Grade 1 (n = 19) . | No. . | Grade 2 (n = 8) . |
|---|---|---|---|---|---|---|---|---|
| Age, y | 69 | 29.0 (22.0–36.0) | 42 | 29.0 (22.2–36.8) | 19 | 29.0 (21.5–36.0) | 8 | 23.5 (18.2–28.0) |
| Sex, female, No. | 69 | 34 (49.3) | 42 | 19 (45.2) | 19 | 10 (52.6) | 8 | 5 (62.5) |
| Illness day at enrollment | 69 | 6.0 (5.0–7.0) | 42 | 6.0 (5.0–7.0) | 19 | 5.0 (4.5–6.0) | 8 | 6.0 (5.8–7.2) |
| Serotype, No. | 69 | 42 | 19 | 8 | ||||
| DENV-1 | 12 (17.4) | 7 (16.7) | 4 (21.1) | 1 (12.5) | ||||
| DENV-2 | 10 (14.5) | 6 (14.3) | 3 (15.8) | 1 (12.5) | ||||
| DENV-3 | 16 (23.2) | 10 (23.8) | 6 (31.6) | 0 (0.0) | ||||
| DENV-4 | 12 (17.4) | 7 (16.7) | 3 (15.8) | 2 (25.0) | ||||
| Unknown | 19 (27.5) | 12 (28.6) | 3 (15.8) | 4 (50.0) | ||||
| Immunostatus, No. (%) | 69 | 42 | 19 | 8 | ||||
| Probable primary infection | 7 (10.1) | 3 (7.1) | 3 (15.8) | 1 (12.5) | ||||
| Probable secondary infection | 35 (50.7) | 21 (50.0) | 10 (52.6) | 4 (50.0) | ||||
| Inconclusive | 27 (39.1) | 18 (42.9) | 6 (31.6) | 3 (37.5) | ||||
| Hepatomegaly, No. (%) | 68 | 5 (7.4) | 42 | 2 (4.8) | 18 | 1 (5.6) | 8 | 2 (25.0) |
| Platelets, ×109/L | 69 | 58.0 (33.0–95.0) | 42 | 53.5 (33.0–105.0) | 19 | 64.0 (38.5–91.0) | 8 | 49.0 (31.5–68.2) |
| White cell count, ×109/L | 69 | 3.6 (2.4–4.7) | 42 | 3.6 (2.5–4.7) | 19 | 2.7 (1.6–4.0) | 8 | 5.5 (3.6–7.5) |
| Neutrophils, ×109/L | 69 | 1.4 (0.8–2.3) | 42 | 1.3 (0.8–2.2) | 19 | 1.3 (0.7–2.1) | 8 | 1.9 (1.0–3.4) |
| Lymphocytes, ×109/L | 69 | 1.0 (0.7–1.9) | 42 | 1.1 (0.8–1.7) | 19 | 0.8 (0.6–1.5) | 8 | 2.0 (1.5–4.4) |
| ALT, IU/L | 37 | 34.0 (27.0–76.0) | 21 | 34.0 (20.0–58.0) | 11 | 47.0 (31.5–116.0) | 5 | 61.0 (34.0–81.0) |
| Viremiaa, log10 copies/mL | 68 | 5.2 (0.0–6.9) | 41 | 4.9 (0.0–6.3) | 19 | 6.6 (5.0–7.6) | 8 | 2.6 (0.0–5.9) |
| WHO classification, No. (%) | 69 | 42 | 19 | 8 | ||||
| Uncomplicated dengue | 18 (26.1) | 16 (38.1) | 2 (10.5) | 0 (0.0) | ||||
| Dengue with warning signs | 46 (66.7) | 26 (61.9) | 16 (84.2) | 4 (50.0) | ||||
| Severe dengue | 5 (7.2) | 0 (0.0) | 1 (5.3) | 4 (50.0) |
| Characteristic . | No. . | All Patients (N = 69) . | No. . | Grade 0 (n = 42) . | No. . | Grade 1 (n = 19) . | No. . | Grade 2 (n = 8) . |
|---|---|---|---|---|---|---|---|---|
| Age, y | 69 | 29.0 (22.0–36.0) | 42 | 29.0 (22.2–36.8) | 19 | 29.0 (21.5–36.0) | 8 | 23.5 (18.2–28.0) |
| Sex, female, No. | 69 | 34 (49.3) | 42 | 19 (45.2) | 19 | 10 (52.6) | 8 | 5 (62.5) |
| Illness day at enrollment | 69 | 6.0 (5.0–7.0) | 42 | 6.0 (5.0–7.0) | 19 | 5.0 (4.5–6.0) | 8 | 6.0 (5.8–7.2) |
| Serotype, No. | 69 | 42 | 19 | 8 | ||||
| DENV-1 | 12 (17.4) | 7 (16.7) | 4 (21.1) | 1 (12.5) | ||||
| DENV-2 | 10 (14.5) | 6 (14.3) | 3 (15.8) | 1 (12.5) | ||||
| DENV-3 | 16 (23.2) | 10 (23.8) | 6 (31.6) | 0 (0.0) | ||||
| DENV-4 | 12 (17.4) | 7 (16.7) | 3 (15.8) | 2 (25.0) | ||||
| Unknown | 19 (27.5) | 12 (28.6) | 3 (15.8) | 4 (50.0) | ||||
| Immunostatus, No. (%) | 69 | 42 | 19 | 8 | ||||
| Probable primary infection | 7 (10.1) | 3 (7.1) | 3 (15.8) | 1 (12.5) | ||||
| Probable secondary infection | 35 (50.7) | 21 (50.0) | 10 (52.6) | 4 (50.0) | ||||
| Inconclusive | 27 (39.1) | 18 (42.9) | 6 (31.6) | 3 (37.5) | ||||
| Hepatomegaly, No. (%) | 68 | 5 (7.4) | 42 | 2 (4.8) | 18 | 1 (5.6) | 8 | 2 (25.0) |
| Platelets, ×109/L | 69 | 58.0 (33.0–95.0) | 42 | 53.5 (33.0–105.0) | 19 | 64.0 (38.5–91.0) | 8 | 49.0 (31.5–68.2) |
| White cell count, ×109/L | 69 | 3.6 (2.4–4.7) | 42 | 3.6 (2.5–4.7) | 19 | 2.7 (1.6–4.0) | 8 | 5.5 (3.6–7.5) |
| Neutrophils, ×109/L | 69 | 1.4 (0.8–2.3) | 42 | 1.3 (0.8–2.2) | 19 | 1.3 (0.7–2.1) | 8 | 1.9 (1.0–3.4) |
| Lymphocytes, ×109/L | 69 | 1.0 (0.7–1.9) | 42 | 1.1 (0.8–1.7) | 19 | 0.8 (0.6–1.5) | 8 | 2.0 (1.5–4.4) |
| ALT, IU/L | 37 | 34.0 (27.0–76.0) | 21 | 34.0 (20.0–58.0) | 11 | 47.0 (31.5–116.0) | 5 | 61.0 (34.0–81.0) |
| Viremiaa, log10 copies/mL | 68 | 5.2 (0.0–6.9) | 41 | 4.9 (0.0–6.3) | 19 | 6.6 (5.0–7.6) | 8 | 2.6 (0.0–5.9) |
| WHO classification, No. (%) | 69 | 42 | 19 | 8 | ||||
| Uncomplicated dengue | 18 (26.1) | 16 (38.1) | 2 (10.5) | 0 (0.0) | ||||
| Dengue with warning signs | 46 (66.7) | 26 (61.9) | 16 (84.2) | 4 (50.0) | ||||
| Severe dengue | 5 (7.2) | 0 (0.0) | 1 (5.3) | 4 (50.0) |
Data are presented as median (interquartile range) unless otherwise indicated.
Abbreviations: ALT, alanine aminotransferase; DENV, dengue virus; WHO, World Health Organization.
There were 18 patients with undetectable viremia at enrollment; all were set as 0 in the log10 scale.
| Characteristic . | No. . | All Patients (N = 69) . | No. . | Grade 0 (n = 42) . | No. . | Grade 1 (n = 19) . | No. . | Grade 2 (n = 8) . |
|---|---|---|---|---|---|---|---|---|
| Age, y | 69 | 29.0 (22.0–36.0) | 42 | 29.0 (22.2–36.8) | 19 | 29.0 (21.5–36.0) | 8 | 23.5 (18.2–28.0) |
| Sex, female, No. | 69 | 34 (49.3) | 42 | 19 (45.2) | 19 | 10 (52.6) | 8 | 5 (62.5) |
| Illness day at enrollment | 69 | 6.0 (5.0–7.0) | 42 | 6.0 (5.0–7.0) | 19 | 5.0 (4.5–6.0) | 8 | 6.0 (5.8–7.2) |
| Serotype, No. | 69 | 42 | 19 | 8 | ||||
| DENV-1 | 12 (17.4) | 7 (16.7) | 4 (21.1) | 1 (12.5) | ||||
| DENV-2 | 10 (14.5) | 6 (14.3) | 3 (15.8) | 1 (12.5) | ||||
| DENV-3 | 16 (23.2) | 10 (23.8) | 6 (31.6) | 0 (0.0) | ||||
| DENV-4 | 12 (17.4) | 7 (16.7) | 3 (15.8) | 2 (25.0) | ||||
| Unknown | 19 (27.5) | 12 (28.6) | 3 (15.8) | 4 (50.0) | ||||
| Immunostatus, No. (%) | 69 | 42 | 19 | 8 | ||||
| Probable primary infection | 7 (10.1) | 3 (7.1) | 3 (15.8) | 1 (12.5) | ||||
| Probable secondary infection | 35 (50.7) | 21 (50.0) | 10 (52.6) | 4 (50.0) | ||||
| Inconclusive | 27 (39.1) | 18 (42.9) | 6 (31.6) | 3 (37.5) | ||||
| Hepatomegaly, No. (%) | 68 | 5 (7.4) | 42 | 2 (4.8) | 18 | 1 (5.6) | 8 | 2 (25.0) |
| Platelets, ×109/L | 69 | 58.0 (33.0–95.0) | 42 | 53.5 (33.0–105.0) | 19 | 64.0 (38.5–91.0) | 8 | 49.0 (31.5–68.2) |
| White cell count, ×109/L | 69 | 3.6 (2.4–4.7) | 42 | 3.6 (2.5–4.7) | 19 | 2.7 (1.6–4.0) | 8 | 5.5 (3.6–7.5) |
| Neutrophils, ×109/L | 69 | 1.4 (0.8–2.3) | 42 | 1.3 (0.8–2.2) | 19 | 1.3 (0.7–2.1) | 8 | 1.9 (1.0–3.4) |
| Lymphocytes, ×109/L | 69 | 1.0 (0.7–1.9) | 42 | 1.1 (0.8–1.7) | 19 | 0.8 (0.6–1.5) | 8 | 2.0 (1.5–4.4) |
| ALT, IU/L | 37 | 34.0 (27.0–76.0) | 21 | 34.0 (20.0–58.0) | 11 | 47.0 (31.5–116.0) | 5 | 61.0 (34.0–81.0) |
| Viremiaa, log10 copies/mL | 68 | 5.2 (0.0–6.9) | 41 | 4.9 (0.0–6.3) | 19 | 6.6 (5.0–7.6) | 8 | 2.6 (0.0–5.9) |
| WHO classification, No. (%) | 69 | 42 | 19 | 8 | ||||
| Uncomplicated dengue | 18 (26.1) | 16 (38.1) | 2 (10.5) | 0 (0.0) | ||||
| Dengue with warning signs | 46 (66.7) | 26 (61.9) | 16 (84.2) | 4 (50.0) | ||||
| Severe dengue | 5 (7.2) | 0 (0.0) | 1 (5.3) | 4 (50.0) |
| Characteristic . | No. . | All Patients (N = 69) . | No. . | Grade 0 (n = 42) . | No. . | Grade 1 (n = 19) . | No. . | Grade 2 (n = 8) . |
|---|---|---|---|---|---|---|---|---|
| Age, y | 69 | 29.0 (22.0–36.0) | 42 | 29.0 (22.2–36.8) | 19 | 29.0 (21.5–36.0) | 8 | 23.5 (18.2–28.0) |
| Sex, female, No. | 69 | 34 (49.3) | 42 | 19 (45.2) | 19 | 10 (52.6) | 8 | 5 (62.5) |
| Illness day at enrollment | 69 | 6.0 (5.0–7.0) | 42 | 6.0 (5.0–7.0) | 19 | 5.0 (4.5–6.0) | 8 | 6.0 (5.8–7.2) |
| Serotype, No. | 69 | 42 | 19 | 8 | ||||
| DENV-1 | 12 (17.4) | 7 (16.7) | 4 (21.1) | 1 (12.5) | ||||
| DENV-2 | 10 (14.5) | 6 (14.3) | 3 (15.8) | 1 (12.5) | ||||
| DENV-3 | 16 (23.2) | 10 (23.8) | 6 (31.6) | 0 (0.0) | ||||
| DENV-4 | 12 (17.4) | 7 (16.7) | 3 (15.8) | 2 (25.0) | ||||
| Unknown | 19 (27.5) | 12 (28.6) | 3 (15.8) | 4 (50.0) | ||||
| Immunostatus, No. (%) | 69 | 42 | 19 | 8 | ||||
| Probable primary infection | 7 (10.1) | 3 (7.1) | 3 (15.8) | 1 (12.5) | ||||
| Probable secondary infection | 35 (50.7) | 21 (50.0) | 10 (52.6) | 4 (50.0) | ||||
| Inconclusive | 27 (39.1) | 18 (42.9) | 6 (31.6) | 3 (37.5) | ||||
| Hepatomegaly, No. (%) | 68 | 5 (7.4) | 42 | 2 (4.8) | 18 | 1 (5.6) | 8 | 2 (25.0) |
| Platelets, ×109/L | 69 | 58.0 (33.0–95.0) | 42 | 53.5 (33.0–105.0) | 19 | 64.0 (38.5–91.0) | 8 | 49.0 (31.5–68.2) |
| White cell count, ×109/L | 69 | 3.6 (2.4–4.7) | 42 | 3.6 (2.5–4.7) | 19 | 2.7 (1.6–4.0) | 8 | 5.5 (3.6–7.5) |
| Neutrophils, ×109/L | 69 | 1.4 (0.8–2.3) | 42 | 1.3 (0.8–2.2) | 19 | 1.3 (0.7–2.1) | 8 | 1.9 (1.0–3.4) |
| Lymphocytes, ×109/L | 69 | 1.0 (0.7–1.9) | 42 | 1.1 (0.8–1.7) | 19 | 0.8 (0.6–1.5) | 8 | 2.0 (1.5–4.4) |
| ALT, IU/L | 37 | 34.0 (27.0–76.0) | 21 | 34.0 (20.0–58.0) | 11 | 47.0 (31.5–116.0) | 5 | 61.0 (34.0–81.0) |
| Viremiaa, log10 copies/mL | 68 | 5.2 (0.0–6.9) | 41 | 4.9 (0.0–6.3) | 19 | 6.6 (5.0–7.6) | 8 | 2.6 (0.0–5.9) |
| WHO classification, No. (%) | 69 | 42 | 19 | 8 | ||||
| Uncomplicated dengue | 18 (26.1) | 16 (38.1) | 2 (10.5) | 0 (0.0) | ||||
| Dengue with warning signs | 46 (66.7) | 26 (61.9) | 16 (84.2) | 4 (50.0) | ||||
| Severe dengue | 5 (7.2) | 0 (0.0) | 1 (5.3) | 4 (50.0) |
Data are presented as median (interquartile range) unless otherwise indicated.
Abbreviations: ALT, alanine aminotransferase; DENV, dengue virus; WHO, World Health Organization.
There were 18 patients with undetectable viremia at enrollment; all were set as 0 in the log10 scale.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
